Hormonal
Once-daily subcutaneous liraglutide (2.4–3.0 mg) combined with a 500 kcal/day caloric deficit and exercise counseling sustains significant weight loss (7.8 kg) and improves cardiovascular risk factors (blood pressure, lipids, prediabetes) over a 2-year period in obese non-diabetic adults.
If you are obese and have not been able to lose weight through diet and exercise alone, adding once-daily liraglutide (2.4-3.0 mg) to a moderate caloric deficit (500 kcal/day) and exercise can help you sustain significant weight loss (around 8 kg) and improve your blood pressure and cholesterol over two years. Expect some initial nausea, which usually subsides, and be prepared for daily injections.
Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.
Why this rating
Randomized, double-blind, placebo-controlled trial with a 2-year extension, large sample size (n=564), and rigorous statistical analysis.
Source
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
on behalf of the NN8022-1807 Investigators et al. · International Journal of Obesity · 2011
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →